First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multi-center phase II trial.

被引：0
|
作者：
Wang, Junsheng
Li, Ning
Guo, Yanzhen
Cheng, Yufeng
Li, Baosheng
Luo, Suxia
机构：
[1] Anyang Canc Hosp, Dept Med Oncol, Anyang, Peoples R China
[2] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Med Oncol, Zhengzhou, Peoples R China
[3] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[4] Qilu Hosp Shandong Univ, Jinan, Peoples R China
[5] Shandong Canc Hosp & Inst, Jinan, Peoples R China
[6] Henan Canc Hosp, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16011
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Nimotuzumab plus paclitaxel and cisplatin as first-line treatment for esophageal squamous cell cancer: A single center prospective clinical trial.
    Zhang, Xiaodong
    Lu, Ming
    Wang, Xicheng
    Li, Jie
    Li, Yan
    Li, Jian
    Zhang, Xiaotian
    Gao, Jing
    Zhou, Jun
    Lu, Zhihao
    Gong, Jifang
    Jia, Jun
    Cui, Yan
    Yu, Jing
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Polymeric micellar paclitaxel plus cisplatin combined with tislelizumab as the first-line treatment of advanced unresectable esophageal squamous cell carcinoma: A phase II study.
    Cao, Guochun
    Li, Xiaoyou
    Liu, Delin
    Zhu, Jinghua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer
    Kim, Jin Young
    Do, Young Rok
    Park, Keon Uk
    Kim, Min Kyung
    Lee, Kyung Hee
    Bae, Sung Hwa
    Ryoo, Hun Mo
    Baek, Jin Ho
    Song, Hong Suk
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (01) : 31 - 36
  • [24] A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer
    Jin Young Kim
    Young Rok Do
    Keon Uk Park
    Min Kyung Kim
    Kyung Hee Lee
    Sung Hwa Bae
    Hun Mo Ryoo
    Jin Ho Baek
    Hong Suk Song
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 31 - 36
  • [25] Nimotuzumab plus paclitaxel and cisplatin as first-line treatment for esophageal squamous cell cancer: Final results of a single-center prospective clinical trial.
    Lu, Ming
    Wang, Xicheng
    Lu, Zhihao
    Li, Jian
    Li, Jie
    Li, Yan
    Zhang, Xiaotian
    Zhou, Jun
    Gong, Jifang
    Jia, Jun
    Yu, Jing
    Cui, Yan
    Shen, Lin
    Zhang, Xiaodong
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase. clinical trial.
    Wang, Junsheng
    Wu, Tao
    Luo, Suxia
    Li, Ning
    Hong, Yonggui
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [27] Preliminary results of TQB2450 (PD-L1 blockade) plus anlotinib combined with oxaliplatin and capecitabine in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, multicenter phase II clinical trial.
    Li, Ning
    Deng, Wen-Ying
    Ma, Yi-Jie
    Bie, Liang-Yu
    Zhang, Chi
    Wei, Chen
    Luo, Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 367 - 367
  • [28] Update results of anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial
    Zhang, Y-F.
    Li, X-B.
    Hong, Y-G.
    Li, X-M.
    Liang, W-M.
    Zheng, Z-X.
    Yang, G-Y.
    Wen, Y-Y.
    Cao, H.
    Wu, W-L.
    Su, W-Z.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1120 - S1120
  • [29] Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
    Zhang, Yan-Feng
    Hao, An-Lin
    Hong, Yong-Gui
    Li, Xiao-Ming
    Liang, Wei-Min
    Zheng, Zhi-Xin
    Yang, Guang-Yi
    Guo, Xiao-Feng
    Wen, Yan-Yan
    Cao, Heng
    Le, Cheng
    Song, Hua-Jie
    Su, Wen-Zhong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16015 - E16015
  • [30] Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial.
    Chen, Yueyun
    Ding, Zhen-Yu
    Yuan, Yong
    Yang, Yu-Shang
    Lin, Zhen
    Tian, Jiangfang
    Liu, Ting
    Yue, Zheng
    Shi, Hua-Shan
    Hu, Yang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 352 - 352
12345